SI1689404T1 - Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka - Google Patents

Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka

Info

Publication number
SI1689404T1
SI1689404T1 SI200430928T SI200430928T SI1689404T1 SI 1689404 T1 SI1689404 T1 SI 1689404T1 SI 200430928 T SI200430928 T SI 200430928T SI 200430928 T SI200430928 T SI 200430928T SI 1689404 T1 SI1689404 T1 SI 1689404T1
Authority
SI
Slovenia
Prior art keywords
combination
cancer
drugs
treatment
fluorouracil
Prior art date
Application number
SI200430928T
Other languages
English (en)
Inventor
Mary Ellen Rybak
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Publication of SI1689404T1 publication Critical patent/SI1689404T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SI200430928T 2003-11-13 2004-11-15 Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka SI1689404T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51969003P 2003-11-13 2003-11-13
EP04798717A EP1689404B9 (en) 2003-11-13 2004-11-15 Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
PCT/GB2004/050026 WO2005049031A1 (en) 2003-11-13 2004-11-15 Combination

Publications (1)

Publication Number Publication Date
SI1689404T1 true SI1689404T1 (sl) 2009-02-28

Family

ID=34619369

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430928T SI1689404T1 (sl) 2003-11-13 2004-11-15 Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka

Country Status (15)

Country Link
US (1) US7622458B2 (sl)
EP (1) EP1689404B9 (sl)
JP (1) JP2007511499A (sl)
AT (1) ATE406897T1 (sl)
CA (1) CA2544320A1 (sl)
CY (1) CY1108629T1 (sl)
DE (1) DE602004016376D1 (sl)
DK (1) DK1689404T3 (sl)
ES (1) ES2314470T3 (sl)
HR (1) HRP20080598T3 (sl)
PL (1) PL1689404T3 (sl)
PT (1) PT1689404E (sl)
RS (1) RS50692B (sl)
SI (1) SI1689404T1 (sl)
WO (1) WO2005049031A1 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
IL155781A0 (en) * 2000-11-06 2003-12-23 Pharma Mar Sa Effective antitumor treatments
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
PL1689404T3 (pl) 2003-11-13 2009-02-27 Pharma Mar Sau Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
BRPI0517238B1 (pt) 2004-10-29 2021-11-09 Pharma Mar, S.A. Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução
AU2006272343B2 (en) * 2005-07-21 2012-09-13 Nuvo Research Ag Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
DK2786756T3 (en) * 2010-11-12 2020-04-27 Pharma Mar Sa Kombinationsterapi med en topoisomeraseinhibitor
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CA3090748A1 (en) * 2018-02-12 2019-08-15 Array Biopharma Inc. Methods and combination therapy to treat biliary tract cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE69936845T2 (de) 1998-04-06 2008-05-08 The Board Of Trustees Of The University Of Illinois, Urbana Halbsynthetische ectein-ascidine
CN100548988C (zh) 1998-05-11 2009-10-14 法马马有限公司 海鞘素743的代谢物
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
PL363110A1 (en) * 2000-02-28 2004-11-15 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
KR100886496B1 (ko) 2000-04-12 2009-03-05 파르마 마르, 에스.에이. 항종양성 엑티나시딘 유도체
AU2001281232A1 (en) 2000-08-11 2002-02-25 City Of Hope The anti-neoplastic agent ET-743 inhibits trans activation by SXR
IL155781A0 (en) * 2000-11-06 2003-12-23 Pharma Mar Sa Effective antitumor treatments
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
EP1435988A4 (en) * 2001-10-19 2008-01-09 Pharmamar Sa IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PL1689404T3 (pl) 2003-11-13 2009-02-27 Pharma Mar Sau Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CN1897949A (zh) 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
CN101068596A (zh) 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
RS50822B (sr) 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
BRPI0517238B1 (pt) 2004-10-29 2021-11-09 Pharma Mar, S.A. Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução

Also Published As

Publication number Publication date
DE602004016376D1 (de) 2008-10-16
DK1689404T3 (da) 2009-01-26
PT1689404E (pt) 2008-12-15
HRP20080598T3 (en) 2009-01-31
EP1689404B1 (en) 2008-09-03
EP1689404B9 (en) 2009-04-22
CA2544320A1 (en) 2005-06-02
ATE406897T1 (de) 2008-09-15
WO2005049031A1 (en) 2005-06-02
JP2007511499A (ja) 2007-05-10
US7622458B2 (en) 2009-11-24
ES2314470T3 (es) 2009-03-16
EP1689404A1 (en) 2006-08-16
RS50692B (sr) 2010-06-30
PL1689404T3 (pl) 2009-02-27
US20070190164A1 (en) 2007-08-16
CY1108629T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
NZ544472A (en) Compounds and therapeutical use thereof
ZA200107920B (en) Apomorphine and sildenafil composition.
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
IL155781A0 (en) Effective antitumor treatments
NO20072543L (no) Anti-cancer-behandling
MY164077A (en) Compositions and uses of et743 for treating cancer
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
WO2000057867A3 (en) Improved cancer treatment with temozolomide
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
PL371741A1 (en) A combination treatment for acute myocardial infarction
AU2001236529A1 (en) Combination therapy for cancer
IL159770A0 (en) Calcium salts with cytotoxic activity
UA11290U (uk) Спосіб профілактики антрациклінового ушкодження серця